Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.
Company profile
Ticker
GMAB, GNMSF
Exchange
Website
CEO
Jan van de Winkel
Employees
Location
Industry (SIC)
SEC CIK
GMAB stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
28 May 24
6-K
Genmab Completes Acquisition of ProfoundBio
21 May 24
6-K
Current report (foreign)
21 May 24
6-K
Current report (foreign)
13 May 24
6-K
Current report (foreign)
8 May 24
6-K
Capital Increase in Genmab as a Result of Employee Warrant Exercise
7 May 24
6-K
Current report (foreign)
6 May 24
6-K
Genmab Announces Financial Results for the First Quarter of 2024
2 May 24
6-K
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
29 Apr 24
6-K
Current report (foreign)
29 Apr 24
Latest ownership filings
144
Notice of proposed sale of securities
1 Mar 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
2 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G/A
BlackRock Inc.
3 Feb 22
SC 13G/A
BlackRock Inc.
29 Jan 21
SC 13G
Beneficial ownership report
7 Feb 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
7.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 226 |
Opened positions | 44 |
Closed positions | 21 |
Increased positions | 92 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 1.66 tn |
Total shares | 47.11 mm |
Total puts | 56.30 k |
Total calls | 36.70 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Alliancebernstein | 9.52 mm | $335.60 bn |
BLK Blackrock | 4.82 mm | $169.91 bn |
Capital International Investors | 4.32 mm | $152.57 bn |
MCQEF Macquarie | 3.25 mm | $114.62 bn |
Harding Loevner | 3.20 mm | $113.01 bn |
Wellington Management | 2.43 mm | $85.54 bn |
1832 Asset Management | 2.24 mm | $79.13 bn |
Renaissance Technologies | 1.17 mm | $41.51 bn |
MS Morgan Stanley | 1.10 mm | $38.82 bn |
First Trust Advisors | 1.09 mm | $38.61 bn |
News
Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer
2 Jun 24
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
24 May 24
What 9 Analyst Ratings Have To Say About Genmab
20 May 24
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
20 May 24
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
3 May 24
Press releases
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
2 Jun 24
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
1 Jun 24
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
1 Jun 24
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
23 May 24
Genmab Completes Acquisition of ProfoundBio
21 May 24